Literature DB >> 32960521

HCG trigger versus GnRH agonist trigger in PCOS patients undergoing IVF cycles: frozen embryo transfer outcomes.

Krishna Deepika1, Rathore Suvarna1, Maria Sumi1, Dhoble Snehal1, Vohra Arveen1, Kamath Anuja1, Pranesh Gautham1, Rao Kamini1.   

Abstract

OBJECTIVE: The use of Gonadotrophin releasing hormone agonist (GnRHa), with freeze-all strategy followed by frozen embryo transfer (FET) has been found to eliminate the risk of ovarian hyperstimulation syndrome (OHSS) in women with polycystic ovarian syndrome (PCOS) undergoing IVF cycles. However, physicians still hesitate to routinely use GnRHa as a trigger, replacing human chorionic gonadotrophin (hCG), for concerns of compromised cycle outcome. We aimed to evaluate outcomes following the transfer of embryos in FET cycles obtained from GnRHa trigger in comparison with hCG trigger in PCOS patients of Asian origin.
METHODS: Prospective observational cohort study. 210 PCOS patients undergoing IVF in an antagonist protocol who were randomized in the previous study (to evaluate if GnRHa trigger is a better alternative than hCG in PCOS patients to prevent OHSS; Group A: GnRHa trigger (n=92)] and Group B: hCG trigger (n=101)], were followed up in FET cycles to assess the outcomes.
RESULTS: The odds of cumulative live birth rate per stimulation cycle favors GnRHa trigger against the hCG trigger [OR=2.15; (CI 1.2-3.83); p=0.008]. A significantly higher number of mature oocytes (19.1±11.7 versus 14.1±4.3; p<0.001) and blastocysts (4.2±1.63 versus 3.26±1.22; p<0.001) were available in the GnRHa group as compared to the hCG group.
CONCLUSION: The cumulative live birth rate was better following transfer of frozen-thawed embryos generated from GnRHa-triggered cycles compared to hCG trigger. Hence, in PCOS undergoing IVF, as a good practice point, hCG trigger should be replaced by a GnRHa trigger with vitrification of all embryos followed by FET.

Entities:  

Keywords:  FET; GnRHa trigger; PCOS; hCG trigger; live birth rate

Mesh:

Substances:

Year:  2021        PMID: 32960521      PMCID: PMC7863104          DOI: 10.5935/1518-0557.20200028

Source DB:  PubMed          Journal:  JBRA Assist Reprod        ISSN: 1517-5693


  64 in total

Review 1.  Preventing ovarian hyperstimulation syndrome: guidance for the clinician.

Authors:  Peter Humaidan; Jens Quartarolo; Evangelos G Papanikolaou
Journal:  Fertil Steril       Date:  2010-04-22       Impact factor: 7.329

2.  A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.

Authors:  E M Kolibianakis; A Schultze-Mosgau; A Schroer; A van Steirteghem; P Devroey; K Diedrich; G Griesinger
Journal:  Hum Reprod       Date:  2005-06-24       Impact factor: 6.918

3.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.

Authors:  G Griesinger; K Diedrich; P Devroey; E M Kolibianakis
Journal:  Hum Reprod Update       Date:  2005-10-27       Impact factor: 15.610

Review 4.  The lutropin/choriogonadotropin receptor, a 2002 perspective.

Authors:  Mario Ascoli; Francesca Fanelli; Deborah L Segaloff
Journal:  Endocr Rev       Date:  2002-04       Impact factor: 19.871

5.  Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support.

Authors:  Tal Imbar; Shahar Kol; Francine Lossos; Yuval Bdolah; A Hurwitz; Ronit Haimov-Kochman
Journal:  Hum Reprod       Date:  2012-01-16       Impact factor: 6.918

6.  GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS.

Authors:  L Engmann; L Siano; D Schmidt; J Nulsen; D Maier; C Benadiva
Journal:  Reprod Biomed Online       Date:  2006-11       Impact factor: 3.828

7.  Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.

Authors:  A Sismanoglu; H I Tekin; H F Erden; N H Ciray; U Ulug; M Bahceci
Journal:  J Assist Reprod Genet       Date:  2009-07-23       Impact factor: 3.412

8.  Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.

Authors:  Daniel Bodri; Juan José Guillén; Anna Galindo; Daniel Mataró; Aïda Pujol; Oriol Coll
Journal:  Fertil Steril       Date:  2008-03-25       Impact factor: 7.329

9.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.

Authors:  Lawrence Engmann; Andrea DiLuigi; David Schmidt; John Nulsen; Donald Maier; Claudio Benadiva
Journal:  Fertil Steril       Date:  2007-04-26       Impact factor: 7.329

10.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

Authors: 
Journal:  Fertil Steril       Date:  2004-01       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.